ANI PHARMACEUTICALS, INC. (NASDAQ:ANIP) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07.
On May 17, 2018, ANI Pharmaceuticals, Inc. (the "Company") held its 2018 Annual Meeting of Stockholders. The following matters, all of which were set forth in the Company's proxy statement for the 2018 Annual Meeting ("Annual Meeting"), were voted on and approved by the Company's stockholders. The voting results for each proposal are set forth below.
1. The individuals listed below were elected at the Annual Meeting to serve as directors of the Company until the next annual meeting of shareholders and until their successors are duly elected and qualified:
| Nominee | For | Against | Abstained | BrokerNon-Votes |
| 1. Robert E. Brown, Jr. | 7,635,697 | 448,905 | 53,786 | 2,016,980 |
| 2. Arthur S. Przybyl | 7,863,844 | 272,879 | 1,665 | 2,016,980 |
| 3. Thomas A. Penn | 6,944,804 | 1,191,909 | 1,675 | 2,016,980 |
| 4. Patrick D. Walsh | 8,031,707 | 104,991 | 1,690 | 2,016,980 |
| 5. David B. Nash, M.D. | 8,030,824 | 105,874 | 1,690 | 2,016,980 |
| 6. Thomas J. Haughey | 8,031,544 | 105,062 | 1,782 | 2,016,980 |
2. The appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the year ending December 31, 2017 2018, as described in the proxy materials, was ratified and approved.
| For | Against | Abstained | Broker Non-Votes |
| 10,115,573 | 33,749 | 6,046 | N/A |
About ANI PHARMACEUTICALS, INC. (NASDAQ:ANIP)
ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company’s focused areas of product development include anti-cancer (oncolytics), hormones and steroids, and complex formulations. Its generic products include Esterified Estrogen with Methyltestosterone, Etodolac, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup, Nimodipine, Opium Tincture, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Lithobid, Reglan and Vancocin. It has over two pharmaceutical manufacturing facilities located in Baudette, Minnesota that are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products. Its two facilities have a combined manufacturing, packaging and laboratory capacity totaling approximately 173,000 square feet.
